Nanoform has filed for GMP status with the Finnish Medicines Agency, FIMEA. The drug substance application for GMP clinical manufacture certification exemplifies its progress and growth in the last 12 months.
Nanoform has appointed Mads Laustsen as a non-executive board member. This appointment will further strengthen the experienced Nanoform board and support the company as it increases its ability to deliver nanonized APIs for global partners across the pipeline from late stage drug discovery to commercial.
Nanoform has appointed Mike Rea as its Strategic Innovation Advisor. The role will involve working closely with Nanoform to maximise the value its proprietary nanonization technology can deliver to pharmaceutical partners and patients globally.
Nanoform has appointed Henri von Haartman as Director of Investor Relations. The newly created role will enrich investor relations as Nanoform seeks to further its shareholder base and continue its international growth, including expansion into the US market.
Nanoform announced the completion of a private placement totaling €10 million, with Ilmarinen Mutual Pension Insurance Company and Mandatum Life Insurance Company (Sampo Group) acting as anchor investors.
Nanoform has unveiled a new brand identity and website. The evolution of Nanoform’s brand reflects how the company is using innovation to transform the pharmaceutical industry and support its global partners as they develop life-changing medicines.
Nanoform accelerates growth with Director of Project Management appointment Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, will appoint Miguel Cansado as its Director of Project Management.
Nanoform awarded with a Seal of Excellence from the European Commission Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has received a Seal of Excellence from the European Commission for its “Nanomedicines of Tomorrow” project.
Nanoform strengthens GMP capabilities with Head of Manufacturing appointment Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has appointed Dr David Rowe as its Head of Manufacturing.
Nanoform strengthens board with appointment of Vice Chairman Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has announced the appointment of Miguel Calado as Vice Chairman of the Board.
Nanoform, an innovative drug enabling nanotechnology company, has announced significant progress in the construction of its new 600m2 GMP manufacturing plant, located at Cultivator II in Viikki Life Science Park, Finland.